A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penns Abramson Cancer Center
Participants who continued tirzepatide kept losing weight
Early studies show that people taking retatrutide usually lose around 1530% of their body weight, with some losing substantially more
Like many other companies, the presentation focused on the companys efforts to expand its pipeline
Note: All cited studies refer to in-vitro and animal model research
For more information, check out our blog that covers the difference between ipamorelin and hexarelin